Evaluating immunologic response and clinical deterioration in treatment-naive patients initiating first-line therapies infected with HIV-1 CRF01-AE and subtype B

Journal of Acquired Immune Deficiency Syndromes

Volumn 62, Issue 3, 2013, Pages 293-300

  Oyomopito, Rebecca A ^a   Li, Patrick C K ^b   Sungkanuparph, Somnuek ^c   Phanuphak, Praphan ^d   Tee, Kok Keng ^e   Sirisanthana, Thira ^f   Kantipong, Pacharee ^g   Oka, Shinichi ^h   Lee, Chris K C ⁱ   Kamarulzaman, Adeeba ^e   Choi, Jun Yong ^j   Sohn, Annette H ^k   Law, Matthew ^a   Chen, Yi Ming A ^l  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^c MAHIDOL UNIVERSITY   (Thailand)

^d THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^e UNIVERSITY OF MALAYA   (Malaysia)

^f CHIANG MAI UNIVERSITY   (Thailand)

^g Chiang Rai Regional Hospital   (Thailand)

^h NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

ⁱ HOSPITAL SUNGAI BULOH   (Malaysia)

^j Yonsei University   (South Korea)

^k TREAT Asia   (Thailand)

^l NATIONAL YANG MING UNIVERSITY   (Taiwan)

more..

Author keywords

Asia; CRF01 Ae; Genotype; HIV 1; Subtype B

Indexed keywords

ABACAVIR; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DEMOGRAPHY; DETERIORATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENOTYPE; HAZARD RATIO; HEPATITIS B; HEPATITIS C; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HONG KONG; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; JAPAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALAYSIA; MALE; MIXED INFECTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PUBLIC HEALTH SERVICE; SOUTH KOREA; TAIWAN; THAILAND; TREATMENT RESPONSE; VIRUS IMMUNITY; VIRUS TRANSMISSION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASIA; CD4 LYMPHOCYTE COUNT; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, VIRAL;

EID: 84876374290     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31827a2e8f     Document Type: Article

References (42)

1. Robertson DL, Anderson JP, Bradac JA, et al. HIV-1 nomenclature proposal. Science. 2000;288:55-56.
2. Korber B, Gaschen B, Yusim K, et al. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull. 2001;58:19-42.
3. Kantor R, Katzenstein D. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev. 2003;5:25-35.
4. Carr JK, Salminen MO, Koch C, et al. Full-length sequence and mosaic structure of a human immunodeficiency virus type 1 isolate from Thailand. J Virol 1996;70:5935-5943.
5. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983;220:868-871.
6. Korber B, Foley BT, Kuiken C, et al. Numbering Positions in HIV Relative to HXB2CG: Theoretical Biology and Biophysics Group. Los Alamos, NM: Los Alamos National Laboratory; 1998.
7. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003;349:2293-2303.
8. Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003;349:2304-2315.
9. Ariyoshi K, Matsuda M, Miura H, et al. Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01-AE (subtype E) infection differ from subtype B infection. J Acquir Immune Defic Syndr. 2003;33:336-342.
10. Dalgleish AG, Beverley PC, Clapham PR, et al. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 1984;312:763-767.
11. Ping LH, Nelson JA, Hoffman IF, et al. Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates fromMalawi: underrepresentation of X4 variants. J Virol 1999;73:6271-6281.
12. Connor RI, Sheridan KE, Ceradini D, et al. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997;185:621-628.
13. Tscherning C, Alaeus A, Fredriksson R, et al. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology. 1998; 241:181-188.
14. Kaleebu P, French N, Mahe C, et al. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis. 2002; 185:1244-1250.
15. Kiwanuka N, Laeyendecker O, Quinn TC, et al. HIV-1 subtypes and differences in heterosexual HIV transmission among HIV-discordant couples in Rakai, Uganda. AIDS. 2009;23:2479-2484.
16. Easterbrook PJ, Smith M, Mullen J, et al. Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J Int AIDS Soc. 2010;13:4.
17. Hemelaar J, Gouws E, Ghys PD, et al. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS. 2011;25:679-689.
18. Kato S, Saito R, Hiraishi Y, et al. Differential prevalence of HIV type 1 subtype B and CRF01-AE among different sexual transmission groups in Tokyo, Japan, as revealed by subtype-specific PCR. AIDS Res Hum Retroviruses. 2003;19:1057-1063.
19. Choi JY, Kim EJ, Park YK, et al. National survey for drug-resistant variants in newly diagnosed antiretroviral drug-naive patients with HIV/AIDS in South Korea: 1999-2005. J Acquir Immune Defic Syndr. 2008;49:237-242.
20. Kim JY, Kim EJ, Choi JY, et al. Genetic variation of the HIV-1 integrase region in newly diagnosed anti-retroviral drug-naive patients with HIV/AIDS in Korea. Clin Microbiol Infect. 2011;17:1155-1159.
21. Chen JH, Wong KH, Chen Z, et al. Increased genetic diversity of HIV-1 circulating in Hong Kong. PLoS One. 2010;5(8):e12198.
22. Tee KK, Li XJ, Nohtomi K, et al. Identification of a novel circulating recombinant form (CRF33-01B) disseminating widely among various risk populations in Kuala Lumpur, Malaysia. J Acquir Immune Defic Syndr. 2006;43:523-529.
23. Chen YJ, Huang YH, Chuang SY, et al. Molecular epidemiology of HIV- 1 subtype B, CRF01-AE, and CRF07-BC infection among injection drug users in Taiwan. J Acquir Immune Defic Syndr. 2010;53:425-439.
24. Kao CF, Chang SY, Hsia KT, et al. Surveillance of HIV type 1 recent infection and molecular epidemiology among different risk behaviors between 2007 and 2009 after the HIV type 1 CRF07-BC outbreak in Taiwan. AIDS Res Hum Retroviruses. 2011;27:745-749.
25. Oyomopito R. Epidemiology and phylogenetic analysis of HIV-1 infection in Asia. In: Monitoring HIV-1 GroupMin the Asia-Pacific: PhD Thesis. Sydney, Australia: Faculty ofMedicine, The University of New South Wales (UNSW); 2011:170-181. Available at: http://handle.unsw.edu.au/1959.4/51620.
26. Hamers RL, Oyomopito R, Kityo C, et al. Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance-HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. Int J Epidemiol. 2012;41:43-54.
27. Zhou J, Kumarasamy N, Ditangco R, et al. The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr. 2005;38:174-179.
28. Sungkanuparph S, Oyomopito R, Sirivichayakul S, et al. HIV-1 drug resistance mutations among antiretroviral-naïve HIV-1-infected patients in Asia: results from the TREAT Asia Studies to Evaluate Resistance- Monitoring Study (TASER-M). Clin Infect Dis. 2011;52:1053-1057.
29. CDC. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged, 18 months and for HIV infection and AIDS among children aged 18 months to, 13 years-United States, 2008. MMWR Recomm Rep. 2008;57:1-16.
30. Tovanabutra S, Watanaveeradej V, Viputtikul K, et al. A new circulating recombinant form, CRF15-01B, reinforces the linkage between IDU and heterosexual epidemics in Thailand. AIDS Res Hum Retroviruses. 2003;19: 561-567.
31. Ng OT, Lin L, Laeyendecker O, et al. Increased rate of CD4+ T-cell decline and faster time to antiretroviral therapy in HIV-1 subtype CRF01-AE infected seroconverters in Singapore. PLoS One. 2011;6(1):e15738.
32. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129.
33. Geretti AM, Harrison L, Green H, et al. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis. 2009;48:1296-1305.
34. DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2011. Available at: http://www.aidsinfo.nih.gov/- ContentFiles/AdultandAdolescentGL.pdf Accessed January 12, 2011.
35. EACS. Guidelines for the clinical management and treatment of HIV infected adults in Europe version 5-2: European AIDS Clinical Society. 2010. Available at: http://www.europeanaidsclinicalsociety.org Accessed January 12, 2011.
36. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000;342:921-929.
37. Oyomopito R. The HIV-1 group M epidemic in the Asia-Pacific. In: Murray JE, ed. Exposure Therapy: New Developments. Hauppauge, NY: Nova Science Publishers, Inc; 2012:295-299. Available at: https://www.novapublishers.com/ catalog/product-info.php?products-id=34906. Accessed May 1, 2012.
38. Li H, Bar KJ, Wang S, et al. High multiplicity infection by HIV-1 in men who have sex with men. PLoS Pathog. 2010;6:e1000890.
39. Heymer KJ, Wilson DP. Available evidence does not support serosorting as an HIV risk reduction strategy. AIDS. 2010;24:935-936.
40. Kaye M, Chibo D, Birch C. Comparison of Bayesian and maximum-likelihood phylogenetic approaches in two legal cases involving accusations of transmission of HIV. AIDS Res Hum Retroviruses. 2009;25:741-748.
41. Zhang M, Foley B, Schultz AK, et al. The role of recombination in the emergence of a complex and dynamic HIV epidemic. Retrovirology. 2010;7:25.
42. Charpentier C, Gody JC, Tisserand P, et al. Usefulness of a genotypic resistance test using dried blood spot specimens in African HIV-infected children with virological failure according to the 2010-revised WHO criteria. Arch Virol 2011;159:1603-1606.